European Society of Clinical Microbiology and Infectious Diseases Yearbook 2018/19 - www.escmid.org
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
European Society of Clinical Microbiology and Infectious Diseases Yearbook 2018/19 www.escmid.org
ESCMID Yearbook
2018/2019 Table of Contents
Society Professional Affairs
2 Message from the ESCMID President 65 Professional Affairs Overview
4 Message from the Secretary General 66 ESCMID Collaborative Centres and
6 Organizational chart Observerships
68 ECDC/ESCMID Observership 2018
Science 69 WHO/ESCMID Observership 2018
8 Scientific Affairs 70 Trainee Association of ESCMID (TAE)
10 Study Groups 72 ESCMID Parity Commission
20 European Committee on Antimicrobial
Susceptibility Testing (EUCAST) in 2018– 2019 International Networking
24 European Committee on Infection 73 ESCMID International Affairs
Control (EUCIC) Subcommittee (EIAS)
28 Emerging infections task force (EITaF) 2018
Awards & Grants
Publications 74 ESCMID Award for Excellence in Clinical
29 Publications Microbiology and Infectious Diseases 2019
30 Clinical Microbiology and Infection 75 ESCMID Young Investigator Awards
32 ESCMID publications for Research in Clinical Microbiology and
40 Medical Guidelines Infectious Diseases 2019
76 ESCMID Research Grants 2019
Education 78 ISF-ESCMID Sepsis Award 2019
44 ESCMID Educational Activities 78 ESCMID TAE Award for Training
46 ESCMID Courses and Workshops Achievements 2019
49 17th ESCMID Summer School
Paris, France, 1–7 July, 2018 Finances
80 Finances
Conferences
50 ESCMID/ASM Conference on Drug Forthcoming Events
Development to Meet the Challenge of 82 Future Congresses
Antimicrobial Resistance 83 Forthcoming Events
Lisbon, Portugal, 4 –7 September, 2018
54 Conference on Antimicrobial Resistance Acknowledgement of Reviewers
from Bench to Practice 84 ECCMID abstract reviewers
Havana, Cuba, 26 – 27 September, 2018 86 ESCMID research grant reviewers
ECCMID 88 Credits
58 28th ECCMID, 21 – 24 April, 2018
in Madrid, Spain
62 29th ECCMID, 13 – 16 April, 2019
in Amsterdam, Netherlands
Message from the ESCMID President infectious diseases and clinical microbiology with
renowned experts and all members of the Executive
The recently created figure of the ESCMID Member-
ship Counsellor (EMeC) provides support for mem-
Committee. While we are also working to increase bers and affiliated partners, representing their inter-
our portfolio of online activities, we still think that ests and also serving as a channel for raising new
face-to-face activities should continue, as they pro- ideas about improving transparency and the open-
vide the additional benefit of personal interaction ness of the Society.
and networking.
The Observership Programme is a very suc- Time to say thank you
“We are convinced that it is through collaboration cessful ESCMID initiative. Because of the huge ESCMID is team work. It is always a good time to
increase in applications for observerships, some acknowledge all those who help to make ESCMID
that we can best contribute to improving the prevention, changes were needed, and the results of the new and ECCMID a success. Of course, we thank all col-
diagnosis and treatment of patients with infections programme will be evaluated over the next year. The leagues who volunteer their time: all Executive Com-
Mentorship programme is under evaluation after the mittee and ad-hoc members, chairs and members of
worldwide, raising awareness of the problems caused pilot phase, and we will probably be opening it to our committees (EUCAST and EUCIC) and subcom-
by neglected and emerging infectious diseases new applications soon. mittees (Education, Scientific Affairs, Publication,
ESCMID is concerned about equity. Our Parity Professional Affairs, International Affairs), the Par-
and spreading the critical role of science in this fight.” Commission is extremely helpful, and their propos- ity Commission, the Trainee Association of ESCMID,
als are always considered very seriously. The Trainee Emerging Infection Task Force, Study Groups, ECCMID
Jesús Rodríguez-Baño Association of ESCMID is also working hard on behalf Programme Committee, and the CMI editorial board.
ESCMID President of younger members and we encourage all trainees More than 200 colleagues dedicate time and talent
jesus.rodriguez-bano@escmid.org to join and help. We continue to work hard to improve to helping ESCMID achieve its mission. Thanks too
gender and geographical balance in all our activities. to our affiliated and sister societies for their contri-
Colleagues from very low-income countries can now bution. My sincere gratitude of course to our Office
ESCMID continues to grow, both in size and scientific in the next 50 years. Awareness and knowledge of benefit from reduced membership fees, and we are staff who carry out their work with amazing com-
influence. While we can justifiably feel proud of this, certain critical problems related to infectious diseas- looking for ways to facilitate their attendance at EC- mitment. Last but not least, I want to express my
I have learned during my first year as President that es is also clearly insufficient at the level of the gener- CMID. We have also created ESCMID CAREer grants to gratitude to all our members, the main driving force
our responsibilities and the complexity of manage- al population. What is more, the information available help members who require childcare for their chil- behind our efforts.
ment have also increased significantly. However, the is sometimes contaminated by fake data (vaccines dren while they are developing a research project.
ESCMID team enjoys challenges, so this one only are a good example). ESCMID can play an important
encourages us to work harder. In fact, we are work- role here through the social networks and other me- An open and transparent Society
ing on a Strategic Plan to help guide the Society over dia, and we are increasing our activity in this area. ESCMID growth must not prove a barrier for anyone
the next 5 years. This Yearbook provides you with an willing to collaborate. We need our structures to be
overview of the activities that were carried out last Guidelines open to our members, their ideas and proposals. We
year. Meanwhile, we continue to think of ways to do Guidelines are a tool for improving care. ESCMID is are working with our Study Groups, Committees and
more and better... committed to dramatically increasing and improv- Subcommittees to improve this as much as possible.
ing our activity in guideline development, both on
International collaboration our own and in collaboration with other societies.
ESCMID is increasingly the home of a large collabora- Beyond that, we are working to develop tools to help
tive network of scientific societies for clinical micro- with the implementation of guidelines and evaluate
biology and infectious diseases from different coun- their impact. We are also aware that the guidelines
tries inside and outside Europe, as well as research methodology can be improved or even rethought,
and professional consortia. We are convinced that it and we are working on innovations in this area too. Executive Committee
is through collaboration that we can best contribute Please see the specific section in this Yearbook for (left to right)
to improving the prevention, diagnosis and treat- further information. Alex W. Friedrich
ment of patients with infections worldwide, raising Emmanuelle Cambau
awareness of the problems caused by neglected and Helping education and career development Maurizio Sanguinetti
emerging diseases and spreading the critical role of We are aware that specialised training in clinical Evelina Tacconelli
science in this fight. We are therefore investing in microbiology and infectious diseases shows consid- Jesús Rodríguez Baño
increasing our collaboration with scientific societies erable heterogeneity across Europe and worldwide. Annelies Zinkernagel
on all continents, learning about their expertise, as Furthermore, our fields are constantly evolving and Mario Poljak
well as the problems and needs in their respective there is a clear need for high-level continuous edu- Önder Ergönül
countries. cational activities. We are therefore continuing to
develop our traditional postgraduate courses and
Advocacy and communication workshops, trying to cover the most critical as-
The importance of microbiology and infectious dis- pects in our fields. From now on, a number of these
eases in human health is obvious to all working in courses will always be held outside Europe in col-
this area but is frequently not adequately reflected at laboration with local organisations. We are proud
the level of political and healthcare management de- to say that our courses and workshops regularly
cisions. Hence, ESCMID is working to explain better to receive very high ratings from attendees. We dedi-
politicians, health authorities and research funding cate special care to the Summer School, where
bodies about the problems and challenges related to 75 trainees and (mostly) young specialists meet
infections that humanity faces right now and will face for a week to learn and to discuss general issues in
2 YEARBOOK 2018/2019 SOCIETY YEARBOOK 2018/2019 SOCIETY 3
Message from the Secretary General
“Probably the most important strength
Total
ESCMID members
2018 8,183
of ESCMID is its extraordinary capability of
combining the two fields of clinical
2,573
microbiology and infectious diseases, which
connected as the two faces of Janus.” 3,545
Maurizio Sanguinetti
ESCMID President-elect and Secretary General
maurizio.sanguinetti@escmid.org Figure 1.
Type of membership
basic 2,065
I can undoubtedly say that this year ESCMID has The positive feedback from the international scientif- full
thrived in terms of membership, influence, and vi- ic community to the plethora of ESCMID activities is young scientist
member type
sion. We now have more than 8,100 members across represented by the high participation in ESCMID an-
130 countries. While Europe still represents the ma- nual congress. Once again, the number of abstracts 251 99
jority of our members (75,53%), we are also proud of received (over 5,300) and participants (just shy
the strong support from the Americas (10.71%) and of 13,000) in the last congress has reached levels
Asia (9.48%). Thanks to our members, ESCMID has never seen before. Of note, there has been a consid- 776
reached a place of absolute prominence compared erable attendance by non-Europeans, documented
to other international scientific societies. One of our by the fact that the United States is the most rep- 876
strengths being the extraordinary capability of com- resented country. ECCMID greatest drawcard is its
bining the fields of clinical microbiology and infec- scientific program that covers all aspects of human
Figure 2.
tious diseases, which stay tied as Janus’ faces. pathogens and infections, including pathogenesis,
Members by continent
Through ESCMID, our valued clinical microbiol- epidemiology, infection control, diagnostics and
Europe
ogy and infectious diseases specialists come face to treatment. Furthermore, ECCMID is able to capture
Americas
face to promote numerous research and educational more and more attention and interest from attend-
Asia 6,181
activities in order to accomplish the mission of im- ees, as it is the place for networking, exchange of
Oceania
proving the diagnosis, prevention and treatment of professional experiences, and identification of part-
Africa
infection-related diseases. We are aware that over ners for future research projects.
the recent years, the tasks to achieve such mission
have become more difficult, and require more ef-
forts and devotion. While we are not yet winning the
battle against emerging and re-emerging infections 700
and antimicrobial-resistant pathogens, we have rec-
ognized the ever-increasing importance of infection 600
control and antimicrobial stewardship. Meanwhile,
we are aware that the scientific and professional 500
community working in both fields need more guid-
ance and/or support in education, research, and 400
career development. In response to that, ESCMID
300
has expanded its commitment by increasing the
number of educational activities, as well as the re- 200
sources dedicated to observership and mentorship
programmes, research grants, international collabo- 100
ration initiatives and the development of medical
guidelines. Of course, this expansion has involved 0
United Kingdom
Spain
Italy
Germany
Netherlands
France
Switzerland
Belgium
United States
Australia
everybody within ESCMID, including the Executive
Committee, Subcommittee members, Study Groups,
Figure 3.
and the Executive Office staff.
Top membership
countries
4 YEARBOOK 2018/2019 SOCIETY YEARBOOK 2018/2019 SOCIETY 5
Organizational chart
Executive Committee (EC) members Ad hoc EC members
Jesús Rodríguez Maurizio Alex W. Friedrich Annelies Önder Ergönül Emmanuelle Mario Poljak Evelina Tacconelli Winfried V. Kern Leonard Leibovici Luigia Scudeller Christian Giske
Baño Sanguinetti Groningen, NL Zinkernagel Istanbul, TR Cambau Ljubljana, SI Tübingen, DE Freiburg, DE Tel Aviv, IL Pavia, IT Stockholm, SE
Seville, ES Rome, IT Zurich, CH Paris, FR Verona, IT
General Affairs General Affairs Finance Science Education Professional Publications Medical Guidelines ECCMID CMI Medical EUCAST
President President-elect & Treasurer & Scientific Affairs Education & Affairs Immediate Past Medical Guidelines Programme Director Editor-in-Chief Guidelines Chairperson
Secretary General Financial Support Officer Communications Professional President & Officer Director
Officer Officer Affairs Officer Publications Officer &
ECCMID Officer
ESCMID Council Scientific Affairs Education Professional Affairs Publication Medical Guidelines ECCMID Programme
Subcommittee Subcommittee Subcommittee Subcommittee Subcommittee Committee
International Affairs
Subcommittee Study Groups Parity Commission,
TAE
Executive Office
Simone Brüderli Andjelka Rasic Daniele Roppolo Luigi Maddaluno William Caddy Benjamin Schirra Carla Seiler Joan Goulley
Chief Operating Accountant Science Manager Science Manager Education Manager Professional Affairs Event Coordination Publications &
Officer & Event Support Manager Medical Guidelines
Coordinator Manager
6 YEARBOOK 2018/2019 SOCIETY YEARBOOK 2018/2019 SOCIETY 7
Scientific Affairs Scientific Affairs Subcommittee
Zeno Bisoffi, Italy (since 2019)
www.escmid.org/science
Oliver Dyar, Sweden (since 2017)
Luigi Gradoni, Italy (until 2018)
Gilbert Greub, Switzerland (until 2018)
Andreas Groll, Germany (until 2018)
Mary Horgan, Ireland (since 2019)
“In addition to awards and funding providing
Mona Johannessen Norway (since 2017)
great motivation, it is the ever-expanding
Souha Kanj, Lebanon (since 2017)
ESCMID network of very knowledgeable Frédéric Laurent, France (since 2017)
scientists and specialists driving the scientific Holger Rohde, Germany (since 2019)
and medical progress of ESCMID forwards.” Kate Templeton, United Kingdom (since 2019)
Carolina Garcia Vidal, Spain (since 2017)
Annelies Zinkernagel Adriana Vince, Croatia (until 2018)
ESCMID Scientific Affairs Officer
annelies.zinkernagel@escmid.org
We are looking back at another productive and in- New year, new people: the new Scientific Affairs
teractive year! Many thanks to all of you and in par- Subcommittee
ticular the study groups and their members, the old One of the major roles of SAS is to assist the Scien-
and new Scientific Affairs Subcommittee members, tific Affairs Officer and the Society in defining Scien-
and all ESCMID members for their fantastic inputs, tific Affairs priorities and supporting science in gen-
support and relentless work. It is a pleasure working eral, and specifically supporting the ESCMID Study
together! Groups. Furthermore, the SAS members carefully an-
In order to reinforce all these efforts we have alyze and evaluate the productivity of the SGs, with
recruited fantastic staff to the ESCMID Office. Wel- the final aim of maximizing their scientific activity.
come aboard! Together, we are looking forward to In 2018, four experienced SAS members com-
another fruitful year. pleted their terms of office: Luigi Gradoni, Gilbert
Greub, Andreas Groll and Adriana Vince. I am thank-
The “engine room” of ESCMID scientific activity: ful to them for their commitment over all these years
the Study groups and for their hard work!
ESCMID Study Groups (SGs) are the core of our Soci-
ety. Through them, ESCMID actively enriches the sci- Starting from January 2019, we are pleased to com-
entific community with new findings, which results in plement our team with Holger Rohde, Kate Temple-
scientific publications, including medical guidelines ton, Mary Horgan and Zeno Bisoffi. I warmly welcome
and textbooks. This is why we guarantee that all SGs the newly appointed members and am looking for-
have adequate scientific and financial resources, ward to working together. I am looking forward to
and we help them set up new collaborations. your new and stimulating inputs!
Our SG community is increasing every year. In
2018, three new SGs were founded: the SG for Res-
piratory Viruses (ESGREV), the SG for Host and Mi-
crobiota Interaction (ESGHAMI) and the SG for Public
Health Microbiology (ESGPHM).
In addition, SGs are always evolving, leading to
the expansion of activity fields. For instance, the SG
for bloodstream infections and sepsis now also cov-
ers endocarditis (ESGBIES) and the SG for Mycoplas-
ma infections now embraces Chlamydia (ESGMAC).
SG scientific meetings and joint conferences
with other international organisations are another
important activity in this portfolio, which the Scien-
tific Affairs Subcommittee (SAS) also oversees. Fi-
nally, as Scientific Affairs Officer, I am enthusiastic
to promote the collaboration of SGs with the ECCMID Scientific Affairs Subcommittee Meeting in 2018
Programme Director in further developing ECCMID (left to right) Luigi Gradoni, Frédéric Laurent, Nancy Gerits (former Guidelines & Publications Manager), Annelies Zinkernagel (Scientific Affairs
scientific programme. Officer), Souha Kanj, Carolina Garcia Vidal, Gilbert Greub, Adriana Vince, Mona Johannessen, Andreas Groll, Daniele Roppolo (Science Manager)
8 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 9
Study Groups
www.escmid.org/studygroups
Here we look back over the many activities per-
formed by our study groups in the calendar year
2018. The following pages show a selection of major
achievements or ongoing activities of the individual a b
study groups. In general the study groups strongly
contribute to ECCMID’s scientific programme by
proposing symposia, educational workshops and
meet-the-expert sessions. They organize the major-
ity of courses/workshops for the ESCMID education c d
programme (see page 44 Education) and publish a
number of scientific articles in ESCMID’s name (see Figure legend: Characteristics of culture of various Mucorales (a–c) on Figure legend: Cultures of different clinical samples on anaerobic blood
page 29 Publications). Sabouraud agar at 37 °C after 4 days of incubation, and fluorescence mi- agar plates incubated for 72h in an anaerobic chamber (Department of
croscopy (d) of a lung biopsy and calcofluor white staining (magnifica- Clinical Microbiology, University of Szeged, Szeged, Hungary) • Co-organisation of the postgraduate course “Challenges in Veter-
tion 100X) displaying broad, unseptate hyphae. inary Hospital Infection Control and Antimicrobial Stewardship”,
• Publication of the article “Sample preparation method influenc- 04/04/2018, Birmingham, United Kingdom
• Organisation of the conference “8th Advances Against Aspergil- es direct identification of anaerobic bacteria from positive blood • Publication of the article “Legal framework of antimicrobial stew-
losis (AAA)”, 31/01 – 04/02/2018, Lisboa, Portugal culture bottles using MALDITOF MS”, Jeverica et al., Anaerobe, ardship in hospitals (LEASH): a European Society of Clinical Mi-
• Organisation of the postgraduate technical workshop “Antifun- 2018. This study was performed in collaboration with ESGAI crobiology and Infectious Diseases (ESCMID) cross-sectional in-
gal Resistance in Candida and Aspergillus: from clinic to clinical • Setting up an International Quality Assurance Scheme for Anaer- ternational survey”, Beovic et al., Int J Antimicrob Agents, 2018
laboratory”, 18 – 21/09/2018, Delhi, India obes (IAQAS) • Contribution to the preparation of the article “ESCMID generic
• Publication of the article “Developing definitions for invasive • Presentation “Ongoing research on Anaerobes in Europe” at the competencies in antimicrobial prescribing and stewardship: to-
fungal diseases in critically ill adult patients in intensive care 14th Biennial Congress of the Anaerobe Society of the Americas, wards a European consensus”, Dyar et al., CMI, 2018
units. Protocol of the FUNgal infections Definitions in ICU pa- 09 – 12/07/2018, Las Vegas, USA
tients (FUNDICU) project”, Mycoses, 2018
Figure legend: Community analysis with a chromogenic media (by Svet- Figure legend: Human intravasal microdialysis to determine the un- Figure legend: Multispecies biofilm containing GFP-producing Pseu-
lana Ugarcina) bound, i.e. antimicrobial active fraction, of antibiotics in vivo; an innova- domonas aeruginosa, stained with wheat germ agglutinin (red) and
tive data source for PK/PD modelling (by Markus Zeitlinger) • Organisation of the post-graduate course “Colistin: the last barri- SYTO44 (blue) (by Eva Vandeplassche)
er for MDR” in collaboration with the Peking Union Medical College
• Organisation of the “International Giardia and Cryptosporidium • Organisation of the course “Optimised dosing of antibiotics – and the Global Chinese Association of Clinical Microbiology and • Publication of the commentary “Should standardized suscepti-
Conference” to be held in Rouen, France, 23–26/06/2019 understanding PK/PD, clinical breakpoints and therapeutic drug Infectious Disease (GCACMID), 25 – 26/05/2018, Beijing, China bility testing for microbial biofilms be introduced in clinical prac-
• Organisation of the symposium “Reservoirs of antimicrobial re- monitoring”, 11 – 12/04/2019, Rotterdam, Netherlands • Increased collaboration with the Central Asian and Eastern Euro- tice?”, Coenye et al., CMI, 2018
sistance genes” at ECCMID 2019, co-arranged with ESGVM, ESGS • Comment on the EMA "Concept paper on preparation of a revised pean Surveillance of Antimicrobial Resistance (CAESAR) network • Organisation of an online course on biofilms, September – Novem-
and ESGARS guideline on the evaluation of medicinal products indicated for • Participation in the INCREMENT-SOT project together with ESGBIES, ber 2018
• Publication of the article “Discrimination of non-typhoid Salmo- treatment of bacterial infections" ESGICH and the Spanish Network for Research in Infectious Dis- • Preparation of the conference “Eurobiofilms2019” to be held in
nella serogroups and serotypes by Fourier Transform Infrared • Organisation of a session at the French national congress of in- eases (REIPI) Glasgow, United Kingdom, 3 – 6/09/2019
Spectroscopy: A comprehensive analysis”, Campos et al., Inter- fectious disease, to be held on 05–07/06/2019, Lyon, France
national Journal of Food Microbiology, 2018. This work was co-
funded with a EFWISG Study Group Research Grant.
10 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 11
Figure legend: Phylogenetic reconstruction of Borrelia species based on Figure legend: International spread of the epidemic Klebsiella pneumoni-
791 aligned protein homologs built with the PEPR pipeline and FastTree2 ae ST258/512 clone. Unrooted phylogenetic tree of 651 isolates of ST258
• New name, new scope: ESCMID Study Group for Bloodstream In- with 100 jackknifed resampling replicates (Margos et al., 2018) • Organisation of the ESCMID/ASID course on infectious diseases and 512. The isolate tips are coloured by the country of isolation (modi-
fied from “Epidemic of carbapenem-resistant Klebsiella pneumoniae in
fections, Endocarditis and Sepsis in pregnant women, foetuses and newborns, 16 – 18/09/2018, Europe is driven by nosocomial spread: Inference from a continent-wide
• Publication of the article “Survival following Staphylococcus au- • Publication of the article “Laboratory support for the diagnosis Sydney, Australia population analysis”, David et al., under review).
reus bloodstream infection: A prospective multinational cohort of Lyme borreliosis: a position paper of ESGBOR, the ESCMID • Support to the project “Toxoplasmosis in Transplant Recipients,
study assessing the impact of place of care”, Nambiar et al., J study group for Lyme borreliosis”, Dessau et al., CMI, 2018 Europe, 2010 – 2014”, Robert-Gangneux et al., Emerging Infec-
Infect., 2018 • Commentary on the WHO ICD11 disease classification codes for tious Diseases, 2018 Co-organisation of the following workshops:
• Organisation of the course “Better methods for clinical studies in Lyme borreliosis • Presentation at the XXXVIII Turkish Microbiology Congress, • “Workshop on Migrants’ Health”, 8–10/03/2018, Muscat, Oman
infectious diseases and clinical microbiology: a hands-on work- • Position on the EU parliament resolution on Lyme borreliosis 04 – 08/11/2018, Antalya, Turkey • “Capacity-Building Workshop: Metagenomics in the Diagnostic
shop”, 7–9/11/2018, Seville, Spain Laboratory”, 21–24/10/2018, Groningen, Netherlands
• “Diagnostic microbiology: MALDI-TOF, bacterial genomics, metagen-
omics, automation and molecular microbiology”, 25–28/09/2018,
Lausanne, Switzerland
Figure legend: The presence of Clostridioides difficile infection surveil- Figure legend: Lung biopsy showing bronchiolitis in a case of respira- Figure legend: Microbiota and One Health (source: www.openclipart.org)
lance system and reference or central laboratories for C. difficile in 2017, tory syncytial virus-associated infant death (by B. Aguilera)
by country (Krutova et al., 2018) • Publication of the review “Management of KPC-producing Kleb- • At their first assembly at ECCMID 2018, members elected the
siella pneumoniae infections”, Bassetti et al., CMI, 2018 • Publication of the review “Post-mortem microbiology in sudden ESGHAMI Executive Committee: Prof. Ed Kuijper (Netherlands),
• Adoption of a new name: ESCMID Study Group for Clostridioides • Organisation of the 2nd Critical Care Conclave, 14/07/2018, Goa, death: sampling protocols proposed in different clinical set- Prof. Benoit Guery (Switzerland) and Prof. Maria Vehreschild
difficile India tings”, Fernandez-Rodríguez et al., CMI, 2018 (Germany) were selected as chair, secretary and treasurer, re-
• Publication of the commentary “The pitfalls of laboratory diag- • Task force on de-escalation therapy in critically ill patients in col- • Presentation of ESGFOR at the meeting. “Animal, Plants and Soil spectively
nostics of C. difficile infection”, Krutova et al., CMI, 2018 laboration with ESCM Traces” organised by the European Network of Forensic Sciences • Membership increased rapidly: 29 people from 16 countries be-
• Co-organiser of the “7th Next Generation Sequencing Work- Institutes, 10–13/04/2018, Pontoise, France come ESGHAMI members by the end of the year
shop on Neisseria gonorrhoeae and Clostridioides difficile”, • Launch of the collaborative project “Targeted 16S-23S rDNA Next • Strong contribution to the ECCMID 2019 scientific programme
21–23/03/2018, Vienna, Austria Generation Sequencing: is it a complementary technique in iden- with co-organisation of 5 sessions
• Collaborative project on the standardization of faecal microbiota tifying an infectious cause of death?”, funded by a ESCMID Study
transplantation for treatment of patients with multiple recur- Group research grant
rences of C. difficile
12 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 13
Figure legend: the ESGIAI app "PJI Database" on the Apple store Figure legend: Metallophilic macrophage rings (green) surrounded by Figure legend: Legionella pneumophila
the red pulp (violet) in the spleen of mice have been identified as the
• Publication of the article “Multidrug (MDR) and extensively drug location in which Streptococcus pneumoniae replicates before causing • Publication of the article “Refugees and family-reunified immi- • Presentation of the results of an ESGLI survey regarding the Se-
resistant (XDR) Gram negative prosthetic joint infections (PJI): invasive disease (Ercoli et al., 2018) grants have a high incidence of HIV diagnosis and late presen- quence Base Typing (SBT) database at the 9th annual meeting of
Role of surgery and impact of colistin administration”, Papado- tation compared with Danish born: a nationwide register-based the European Legionnaires’ disease surveillance network (ELD-
poulos et al., Int J Antimicrob Agents, 2018 • Support to the publication “Combined effect of non-bacteriolytic cohort study”, Deen et al., Infection, 2018 SNET), by Dr Victoria Chalker, Lyon, France
• Organisation of the ESCMID Postgraduate Course “Update on antibiotic and inhibition of matrix metalloproteinases prevents • Presentation at the International Alliance for the control of • Organisation of the “5th meeting of the ESCMID Study Group for
Endocarditis and Endovascular Infections”, 20–23/03/2018, brain injury and preserves learning, memory and hearing func- Scabies: “Mass drug administration in asylum seekers in New Legionella Infections”, 28–30/08/2018, Lyon, France
Muenster, Germany tion in experimental paediatric pneumococcal meningitis”, Muri Orleans” by Prof. Ymkje Stienstra, on behalf of ESGITM • Obtained ECDC travel grants for the projects “Antimicrobial resist-
• Development of the free-of-charge application “PJI Database” that et al., Journal of Neuroinflammation, 2018 • Co-organisation of the “International Conference on Migration ance in Legionella” and “Legionella SBT database WGS meeting”
helps researchers collect clinical data on periprosthetic joint in- • Organisation of the ESCMID Postgraduate Education Course Health”, 13/10/2018, Rome, Italy
fections and creates a common database for prospective studies “Acute Bacterial CNS Infections of the Brain”, 11–13/10/2018,
Munich, Germany
• Publication of the systematic review “Diagnostic value of cer-
ebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A sys-
tematic review and meta-analysis”, Rupprecht et al., CMI, 2018
Figure legend: Mode of action of T-lymphocyte associated antigen 4 Figure legend: Mycoplasma pneumoniae infecting A549 cells (by Roger Figure legend: Methods to identify microorganisms from positive blood
(CTLA-4)-targeted agents. Ipilimumab and tremelimumab are monoclo- Dumke) cultures or blood (Peker et al., CMI, 2018)
nal antibodies that bind CTLA-4, thus preventing engagement by agonist • Publication of the review “Antimicrobial consumption and impact
ligands like B7-1 (CD80) and B7-2 (CD86), and blocking its inhibitory ef-
fect on T-cell priming (from Redelman-Sidi et al, 2018, part of the ESGICH of antimicrobial stewardship programmes in long-term care fa- • New name, new scope: to study and understand the clinical • Publication of the commentary “Diagnostic stewardship: are we
Consensus Document on the safety of targeted and biological therapies) cilities”, Falcone et al., CMI, 2018 presentation, and the epidemiology (including development of using the right term?”, Dyar et al., CMI, 2018
• Organisation of the postgraduate course “Infection in Older Popu- antimicrobial resistance) of Mycoplasma, Ureaplasma, Chla- • Organisation of the 3rd course on “Principles of Molecular Micro-
lations: The next Challenges”, 12–14/09/2018, Grenoble, France mydia and Chlamydophila infections in humans as well as to biological Diagnostics”, 17–19/01/2018, Maastricht, Netherlands
• Publication of the “ESGICH consensus document on the safety of • Support to the publication “Serum albumin is a strong predictor improve diagnosis, treatment, control and prevention • Prof. John Rossen, ESGMD chair, represented ESCMID at ”LMCE
targeted and biologic therapies: an infectious diseases perspec- of sepsis outcome in elderly patients”, Arnau-Barrés et al, CMI, • Co-organisation of a symposium on antimicrobial Resistance 2018 & 59th KSLM Annual Meeting”, where he gave the talk
tive”, CMI, 2018 2018 at the “International Organization for Mycoplasmalogy meeting “Next generation sequencing in routine clinical microbiology”,
• Organisation of the conference “Antimicrobial Therapy in Immu- (IOM)”, 9–12/07/2018, Portsmouth, USA 1–3/11/2018, Seoul, South Korea
nocompromised and Critically Ill Patients: Management and Per- • Allocation of four student awards to ESGMAC members present-
spectives”, 4–5/10/2018, Lugano, Switzerland ing posters at the IOM meeting
• Participation at the “20th Symposium on Infections in the Immu-
nocompromised Host”, 17/06/2018, Athens, Greece
14 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 15
Figure legend: Coloured scanning electron micrograph of a staphylococ- Figure legend: HCV cascade of care
cal biofilm observed at Centre Technologique des Microstructures, Lyon,
• Publication of the perspective article “Insights on Mycobacte- • Publication of the research article “Variability in contact precau- France. Free Staphylococcus aureus (blue) or embedded in biofilm (red); • Publication of the review “Hepatitis C elimination among people
rium leprae Efflux Pumps and Their Implications in Drug Resist- tions to control the nosocomial spread of multi-drug resistant polystyrene matrix (green); coloration by Margot Zussy. who inject drugs: Challenges and recommendations for action
ance and Virulence”, Machado et al., Front. Microbiol., 2018 organisms in the endemic setting: a multinational cross-section- within a health systems framework”, Day et al., Liver Int, Epub
• Organisation of the post graduate educational course “Manage- al survey”, Vuichard Gysin et al., Antimicrobial Resistance and • Publication of the article “European external quality assess- 2018
ment of mycobacterial infections and associated comorbidities”, Infection Control, 2018 ments for identification, molecular typing and characterization • Collaboration with the “Hepatitis C antiviral therapy failure Reg-
27–28/09/2018, Rome, Italy • Publication of the book “Clinically Relevant Mycoses. A Practical of Staphylococcus aureus”, Deplano et al., J Antimicrob Chem- istry (HepCaRe)” organised by the European Society for Transla-
• Participation in the 3rd EUCAST-ESGMYC Subcommittee meeting Approach”, Springer, 2018 other, 2018 tional Antiviral Research (ESAR). This European database is set
on antimycobacterial susceptibility testing, 21/04/2018, Madrid, • Member of the Scientific Committee of the “International Confer- • Co-organisation of the “18th International Symposium on Staph- up to systematically collect data on anti-HCV therapy failure
Spain ence on One Health Antimicrobial Resistance (ICOHAR)” to be ylococci and Staphylococcal Infections”, 23–26/08/2018, • Co-organisation of the “Workshop on Migrants’ Health”,
held in April 2019, Utrecht, Netherlands Copenhagen 8 –10/03/2018, Muscat, Oman
• Preparation of literature review for the joint IDSA-ESCMID pro-
ject “Practice Guideline on the Management of S. aureus Blood-
stream Infection”
Figure legend: Influenza A virus detected by immunofluorescence in Shell Figure legend: The mutant selective window (MSW) delimitates the range
vial after 24 hours growth of antimicrobial concentrations selecting for the resistant mutants, which
• At their first assembly at ECCMID 2018, members elected the range from the mutant prevention concentration (MPC) to the MIC of the • Publication of the review “Vaccination of 50+ adults to promote
ESGPHM Executive Committee: Titia Kortbeek (Netherlands): • At their first assembly at ECCMID 2018, members elected the initial bacterial population (modified from Guardabassi et al., 2018) healthy ageing in Europe: The way forward”, Esposito et al., Vac-
chair; Androulla Efstratiou (United Kingdom): co-chair; Georgina ESGREV Executive Committee: Dr Chrysanthi Skevaki (Germa- cine, 2018
Tzanakaki (Greece): scientific secretary; Silvia Herrera Leon ny): chair; Prof. Sotirios Tsiodras (Greece): secretary; Dr Stefan • Publication of the book chapter “Optimization of Antimicrobial • Co-organisation of the consensus conference on pertussis re-
(Spain): treasurer; additional members: Andreas Sing (Germany), Paul Kuster (Switzerland): treasurer; additional members: Treatment to Minimize Resistance Selection”, Guardabassi et al., surgence, 22/06/2018, Perugia, Italy
Steven Vangucht (Belgium), Rune Stensvold (Denmark) Prof. Barbara Rath (Germany), Kate Templeton (United Kingdom) Microbiol Spectrum, 2018 • Organisation of the course “Adult Immunization: New and Old
• The first ESGPHM newsletter was sent to the members in Novem- • Preparation of the Study Group bylaws and promotion of the • Collaboration with VetCAST for the organisation of the workshop Challenges”, 16–17/03/2018, Sao Paulo, Brazil
ber 2018 ESGREV membership (27 members by the end of the year) “Determination of clinical breakpoints”, 22/06/2018, Wroclaw,
• ESGPHM is member of the scientific committee of the 12th Inter- • Co-organisation of three sessions at ECCMID 2019 Poland
national Meeting on Microbial Epidemiological Markers (IMMEM • Organisation of the course “Challenges in Veterinary Hospital
XII) to be held on 18–21/09/2019, Dubrovnik, Croatia Infection Control and Antimicrobial Stewardship”, 04/04/2018,
Birmingham, United Kingdom
16 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 1718 YEARBOOK 2018/2019 ECCMID YEARBOOK 2018/2019 ECCMID 19
European Committee on Antimicrobial Antifungal Susceptibility Testing Subcommittee (AFST)
AFST continued with their work on breakpoints and methods for
Subcommittee on antimycobacterial agents (AMST)
The Subcommittee on antimycobacterial agents was formed with
Susceptibility Testing (EUCAST) in 2018 – 2019 antifungal agents. The AFST General Subcommittee met once on
22 April, Madrid, Spain, during ECCMID 2018. The Steering Subcom-
the aim of examining methods of susceptibility testing of Myco-
bacterium tuberculosis, and ascertaining whether a reference
www.eucast.org mittee met on the following dates: January 18 – 19, Prague, Czech method could be established, which would allow the development
Republic; 21 April, Madrid, Spain; and October 8 – 9, Milan, Italy. and setting of breakpoints for antitubercular agents. It is chaired
by Emmanuelle Cambau, France and Thomas Schön, Sweden is the
During the contract period: Scientific Secretary.
“In 2019, the definition of the susceptibility testing • The voriconazole rationale document was updated and published Significant progress has been made in multi-lab pilot testing
on the website. of a reference method.
interpretive category “I” was changed to a • A screening method for azole resistance in Aspergillus fumi- The Subcommittee met once face-to-face in April 2018, in Ma-
single meaning: “Susceptible, Increased exposure”, gatus (E.Def 10.1) was developed and published in Clinical drid, Spain, during ECCMID.
Microbiology and Infection and a link provided on the EUCAST
implying adequate response to treatment website. Subcommittee on wild type MIC distributions and epidemiological
when the antimicrobial dosing regimen is adjusted cut-off values (ECOFFs)
AFST undertook the following activities during the report period: The subcommittee, chaired by Gunnar Kahlmeter, Sweden, was es-
to increase pathogen exposure.” • Examination of different plastic plates types and brands used for tablished early 2016, with the remit to define:
broth microdilution susceptibility testing (potential for drug ad- • Standards for MIC distributions required for ECOFF calculation,
Christian Giske herence). • Methods used to set ECOFFs and
EUCAST Chairman • Conduction of a multi-centre MIC data study for epidemiological • Conditions for revision of ECOFFs
christian.giske@escmid.org cut-off values (ECOFF) setting.
• Work on alternative methods for echinocandin testing. The subcommittee finalised a proposal on how to accept MIC dis-
• Determination of in vitro PK-PD breakpoints for azoles and tributions (www.eucast.org/mic_distributions_and_ecoffs), and on
EUCAST provides breakpoints and antimicrobial susceptibility test- (Germany), Christoffer Lindemann (Norway), and Johan Mouton Candida non-albicans spp. how to define tentative ECOFFs and ECOFFs (SOP 10,0). The MIC
ing methods on a global scale. ESCMID is the administrative, finan- (Netherlands). distribution website is continuously updated as data and ECOFFs
cial and scientific framework for EUCAST. ESCMID (www.escmid.org), Veterinary Subcommittee on Antimicrobial Susceptibility Testing are revised according to the new procedures.
the ESCMID Förderverein (www.escmid-fv.org) and the Europe- EUCAST General Committee (VetCAST)
an Centre for Disease prevention and Control (ECDC; www.ecdc. The annual open meeting for national representatives on the Gen- The VetCAST General Subcommittee met once in April, during Subcommittee on antimicrobial susceptibility testing by whole
europa.eu) supported EUCAST financially in 2018. ESCMID also eral Committee was held during ECCMID 2018, Madrid, Spain, where ECCMID 2018, and once during the report period at Schiphol Airport, genome sequencing (WGS)
supports the development of the EUCAST disk diffusion method, the preceding year’s activities and future plans were reviewed. Amsterdam, Netherlands, 26 March, 2018. VetCAST has undertaken Following the successful first edition of the role of WGS in suscep-
and the EUCAST microdilution methods for fungi. The General Committee representatives of the Steering Committee the following activities during the report period: tibility testing, a review has commenced considering that this is a
were Cidalia Pina Vaz, Portugal and Efi Petinaki, Greece. • Collection of MIC distribution and pharmacokinetic-pharmacody- rapidly evolving field.
EUCAST Steering Committee namic data for the initial stages of breakpoint setting, starting
The Steering Committee met five times during 2018 and dealt with National AST Committees (NACs) with tetracyclines. EUCAST network laboratories
many aspects of breakpoints and antimicrobial susceptibility test- NACs provide national input on all aspects of EUCAST, promote • Nearing completion of breakpoints and a rationale document for EUCAST Network Laboratories are committed to help develop, vali-
ing. “Visiting” General Committee members, European Medicines national strategies for susceptibility testing and help implement florfenicol. date and troubleshoot EUCAST AST/AFST methods and/or to help
Agency (EMA) representatives and/or ECDC representatives at- EUCAST breakpoints and methods. • Release of a document describing the remit and activities of train and educate other laboratories in EUCAST methods. They
tended several meetings. Groups from three pharmaceutical com- Nearly all European countries have established NACs. Fur- VetCAST on the EUCAST website. also play an important role in improving methods and/or assisting
panies gave presentations to the committee, all providing data on ther efforts to recruit the remaining EU/EEC member countries are • Release of “VetCAST Guidance on how to collect and handle clinical breakpoint development by providing species-specific MIC
a new agent. ongoing. Interest in EUCAST in countries outside the European Un- PK data”. datasets. These labs have specific expertise and training in EUCAST
The composition of the 2018 Steering Committee was as fol- ion continues to increase. Several countries are currently in the Antimicrobial Susceptibility Testing (AST) for bacteria and EUCAST
lows: Christian Giske, Chairman, John Turnidge, Scientific Secretary, process of developing NACs with the European Union and beyond. In 2018, the first Chair of VetCAST, Dik Mevius, Netherlands, stepped Antifungal Susceptibility Testing (AFST) methods.
Rafael Cantón, Clinical Data Coordinator, and Gunnar Kahlmeter, Tech- The Chinese NAC (ChiCAST) held a EUCAST-focused meeting at down and was replaced by Peter Damborg, Denmark. In turn, Peter The work on developing the structure of “EUCAST Network Lab-
nical Data Coordinator. Regular Steering Committee members were ECCMID 2018. Damborg was replaced as Scientific Secretary by Gudrun Overesch, oratories” continued in 2018. Currently, 14 bacterial and 11 mycol-
Alasdair MacGowan (UK), Gerard Lina (France), Sören Gatermann Switzerland. ogy laboratories have joined the network.
Steering Committee, April 2018 Steering Committee Chair, Christian Giske The Antifungal Susceptibility Testing Subcommittee, April 2018 The Subcommittee on antimycobacterial agents, April 2018
20 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 21For more information and for laboratories interested in participating, without recommendations. Quality controls (QC) ranges are estab-
please visit “The EUCAST AST Network Laboratories” on the EUCAST lished for new agents and organisms and older QC ranges may be
website. revised if required. EUCAST is working with the Clinical and Labora-
tory Standards Institute (CLSI) to harmonise procedures for select-
EUCAST breakpoints ing disk potencies used for disk diffusion testing. A joint EUCAST/
Version 9.0 of the MIC and zone diameter breakpoint tables for bac- CLSI working group has been established.
teria and QC tables were published on the EUCAST website in Janu-
ary 2019. EUCAST website
Breakpoints for new agents are set by EUCAST as part of the The EUCAST website (www.eucast.org) is continuously updated. All
marketing authorisation process by the European Medicines Agen- significant changes are highlighted in the “News” section and a
cy (EMA). In the past year, breakpoints were proposed for eravacy- list of all changes is available via the “Website changes” link below 120,000 Figure 1.
cline, delafloxacin and meropenem-vaborbactam. The breakpoints the contents list. Documents updated in 2018 include: breakpoint Unique pageviews for
for several other new agents are being evaluated. tables, QC tables, standard operating procedures (SOPs), files list- eucast.org 2016 – 2018
100,000
Breakpoints for oral amoxicillin for Haemophilus influenzae ing calibration and validation of disk diffusion testing vs. MIC, read- 2018
and Streptococcus pneumoniae, as well as breakpoints for carbap- ing guides and method descriptions, frequently asked questions 2017
enems and tigecycline were revised. (FAQs), compliance of manufacturers and validation documents 80,000 2016
In January 2019 EUCAST introduced a revised susceptibility for MIC and inhibition zone diameter correlations.
categorisation, emphasising the relationship between breakpoints Figure 1 provides an overview of the unique page visits to the 60,000
and exposure of the microorganism: EUCAST website, indicating a steady increase over the years.
S) Susceptible, standard dosing regimen
40,000
I) Susceptible – Increased exposure EUCAST consultations
R) Resistant Many of the EUCAST documents on the website were updated in
2018 and this is an ongoing process. Rationale documents, giv- 20,000
This was accompanied by the introduction of the concept of Area ing background data and providing the rationale for EUCAST break-
of Technical Uncertainty (ATU) for antimicrobial-organism combi- points, continue to be developed. EUCAST Expert Rules are being 0
nations that have a small region of uncertainty in categorisation, updated by the Steering Committee.
January
February
March
April
May
June
July
August
September
October
November
December
requiring the testing laboratory to take further action. Detailed in- A summary of consultations can be found at www.eucast.org/
formation about the changes and their consequences is available documents/consultations. All EUCAST documents are freely avail-
at www.eucast.org/newsiandr. able on the EUCAST website.
EUCAST disk diffusion method 2018 publications
The EUCAST Development Laboratory (Växjö, Sweden), in collabora- EUCAST published or contributed to 6 publications in 2018 (Table 1).
tion with EUCAST Network Laboratories, develops EUCAST suscepti- The most important publications include one on the problems of
bility testing methods, including disk diffusion methods and zone testing colistin, and one on patient safety issues arising from the
diameter breakpoints for new agents and for organisms currently lack of standardised codes for antimicrobials disks. MIC-based dose adjustment: facts and fables. International request to standardise antimicrobial disk codes
Mouton JW, Muller EA, Canton R, Giske CG, Kahlmeter G, Turnidge JJ for patient safety and a method for creating new codes
Antimicrobial Chemother 2018, 3;564–568, A plea from EUCAST for standardization of disc susceptibility
testing antimicrobial codes.
Turnidge J, Lina G, Giske C; European Committee on Antimicrobial
Development of EUCAST zone diameter breakpoints and quality Susceptibility Testing (EUCAST) Steering Committee. Clin Microbiol
control criteria for ceftazidime-avibactam 10-4 μg. Infect. 2018 pii: S1198-743X(18)30579-2
Koeth LM, Matuschek E, Kahlmeter G, Stone G. Eur J Clin Microbiol Infect
Dis. 2018;37(6):1047–1053
Detailed description of the EUCAST AFST-developed method for
screening for azole resistance in A. fumigatus
Evaluation of antimicrobial disk quality from nine manufacturers How to: EUCAST recommendations on the screening procedure
The quality of antimicrobial discs from nine manufacturers-EUCAST E.Def 10.1 for the detection of azole resistance in Aspergillus
evaluations in 2014 and 2017. fumigatus isolates using four well azole-containing agar plates.
Åhman J, Matuschek E, Kahlmeter G. Clin Microbiol Infect. 2018: Guinea J, Verweij PE, Meletiadis et al. Clin Microbiol Infect. 2018 pii:
S1198-743X(18)30456–7 S1198-743X(18)30630-X
Evaluation of colistin susceptibility testing Colistin antimicrobial susceptibility testing-can the slow and
Antimicrobial susceptibility testing of colistin – evaluation of seven challenging be replaced by the rapid and convenient?
commercial MIC products against standard broth microdilution for Giske CG, Kahlmeter G. Clin Microbiol Infect. 2017 pii: S1198-
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 743X(17)30569-4
and Acinetobacter spp.
Matuschek E, Åhman J, Webster C, Kahlmeter G. Clin Microbiol Infect.
2018;24(8):865–870
The VetCAST Subcommittee and meeting attendees, April 2017 Table 1. 2018 publications
22 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 23European Committee on Infection Control (EUCIC) Overview of the EUCIC modules
Infection prevention & control: an ESCMID priority!
www.escmid.org/eucic 2018 2019
JANUARY
Freiburg, Germany: Dynamics of disease transmission:
from genomes to infection control
“In infection control the collaboration among FEBRUARY
Groningen, Netherlands: EUCIC basic module Bucharest, Romania: Biofilm-driven infections research
stakeholders and countries and effective and clinical relevance
education are essential for success. EUCIC is
MA R C H
proudly contributing to the education of a Ljubljana, Slovenia: Antimicrobial stewardship
new generation of infection control specialists
APRIL
with global knowledge and expertise.” Loures, Portugal: Practical infection control skills Heraklion, Greece: Implementation of surveillance
Evelina Tacconelli, EUCIC Chair MAY
evelina.tacconelli@escmid.org Bergamo, Italy: Development and implementation
Geneva, Switzerland: Science of implementation
Nico T. Mutters, EUCIC Scientific Coordinator
in infection control
nico.mutters@uniklinik-freiburg.de
Athens, Greece: Microbiological diagnostic skills
Alex W. Friedrich, EUCIC Clinical Coordinator
alex.friedrich@escmid.org JUNE
Zagreb, Croatia: Antimicrobial therapy and stewardship
Nicosia, Cyprus: Surveillance and meta-competence
EUCIC guidelines research_projects/eucic/training_programme) and come and visit
The first EUCIC guidelines has been published in January 2019! the ESCMID booth at ECCMID 2019. J U LY
These evidence-based guidelines were produced after a system- Paris, France: Surveillance and early warning systems of
atic review of published studies on decolonization interventions EUCIC and UEMS healthcare-associated infections
targeting multidrug-resistant Gram negatives including carbapen- The Union Européenne des Médecins Spécialistes (UEMS) council
em-resistant Enterobacteriaceae and carbapenem-resistant Acine- approved the implementation of a multidisciplinary joint commit- SEPTEMBER
tobacter baumannii. The recommendations are grouped by species tee on infection control (MJC IC), on the initiative of EUCIC, UEMS Nicosia, Cyprus: Surveillance and meta-competence Vienna, Austria: Technical hygiene
and include faecal microbiota transplantation. Four types of out- infectious diseases (ID) and UEMS medical microbiology (MM).
comes were evaluated for each bacteria: The UEMS President, Prof. Romuald Krajewski, asked MJC IC to OCTOBER
a) microbiological outcomes (carriage and eradication rates) collaborate with all specialties represented in UEMS, in the prepa- Porto, Portugal: Antimicrobial therapy and stewardship
b) clinical outcomes (attributable and all-cause mortality and ration of their core competencies, in order to incorporate principles Utrecht, Netherlands: Epidemiology and data analysis in
infection incidence) of infection control in their curriculum. Since full implementation infection control
c) epidemiological outcomes (acquisition incidence, transmission of infection control measures can only be accomplished with a
and outbreaks) multidisciplinary work, invitations were sent out to all UEMS sec- NOVEMBER
d) adverse events (including resistance development). tions. The scope of MJC IC is education of European Medical Special- Matosinhos, Portugal: Implementation science and Cologne, Germany: Advanced training for infection control/
ties. Their own core curricula should incorporate infection control management hospital hygiene and targeted prevention measures
The level of evidence for and strength of each recommendation standards. Objectives of the MJC IC:
were defined according to the GRADE approach. Guidelines are free- • To contribute to the definition of European standards of medical DECEMBER
ly available on ESCMID and CMI websites. education and training in infection control. Madrid, Spain: Meta-competence and European competence
• To make European Infection Control core competencies available
EUCIC training as a cornerstone to harmonize infection prevention and control
We are pleased to announce that the European Committee on In- training and education in Europe.
fection Control (EUCIC) has made some substantial progress over • Ensure that part of the curriculum and European training re- Advanced & basic module
the past year. The 2-year EUCIC Infection Prevention and Control quirements pertaining to IC in both ID and MM specialties are Local module
Certificate – European Training Programme has been launched and structured in a similar way.
has now successfully completed its first year. A total of 36 train- • To set up a European Certificate in Infection Control for medical
ees from 15 countries were enrolled. As part of the programme, the specialists, in collaboration with EUCIC, ECDC, and other relevant
European Centre for Disease Control (ECDC) successfully contrib- stakeholders.
uted to the surveillance module held in Paris and the outbreak
module held in Utrecht in 2018, which strengthened the collabora- Composition of the MJC IC Board: President: Nicola Petrosillo, Italy
tion between EUCIC and ECDC. The figure showing the distribution (ID); Vice-president: Maeve Doyle, Ireland (MM); Secretary: Davor-
of modules around Europe and their timeline can be found on the ka Dušek, Croatia (ID); Treasurer: Breida Boyle, Ireland (MM).
following pages. We are planning to launch a second semester of
trainees completing the programme in 2020/21. For more infor- EUCIC and WHO
mation, please consult the dedicated website (www.escmid.org/ The Global Infection Prevention and Control Network (GIPCN) of the EUCIC meeting 2018
24 YEARBOOK 2018/2019 SCIENCE YEARBOOK 2018/2019 SCIENCE 25You can also read
